logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
E

Eisaku Miyauchi

Tohoku University Hospital
H指数:20
被引数:1,250

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plain language summary of the J-TAIL-2 study results: a study of Japanese patients with extensive-stage small cell lung cancer that followed their treatment with atezolizumab plus chemotherapy over time

J-TAIL-2研究结果的简明摘要：一项关于日本广泛期小细胞肺癌患者接受阿替利珠单抗联合化疗长期随访的研究

Future Oncology
IF2.6
2026-10-010
OA
Eisaku Miyauchi; Makoto Nishio; Kadoaki Ohashi; Atsushi Osoegawa; Eiki Kikuchi; Hideharu Kimura; Yasushi Goto; Junichi Shimizu; Hiroshige Yoshioka; Ichiro Yoshino; Toshihiro Misumi; Nobuyuki Katakami; Masahide Oki; Takashi Kijima; Kenichi Chikamori; Kazumi Nishino; Takuma Arai; Kenichiro Ieda; Akihiko Gemma
Clinical utility of comprehensive genomic profiling tests using MTB management system at a single center in Japan

日本单中心利用MTB管理系统进行综合基因组分析测试的临床应用价值

Scientific Reports
IF3.9
2026-07-070
OA
Chie Sarudate; Miki Dobashi; Maako Kawamura; Hidekazu Shirota; Tomoyuki Iwasaki; Hiroshi Tada; Muneaki Shimada; Naoki Kawamorita; Masayuki Kanamori; Eisaku Miyauchi; Hidetaka Niizuma; Yuki Kasahara; Kota Ouchi; Hiroo Imai; Ken Saijo; Keigo Komine; Masanobu Takahashi; Toru Furukawa; Aya Yokota; Eiji Kanamori; Hisato Kawakami; Chikashi Ishioka
Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study

依匹木单抗联合纳武利尤单抗，联合或不联合化疗，根据基线肿瘤大小评估其疗效：一项多中心回顾性研究

Translational Lung Cancer Research
IF3.5
2026-06-300
PRE
Tanaka, Hisashi; Makiguchi, Tomonori; Tozuka, Takehiro; Kawashima, Yosuke; Oba, Tomohiro; Tsugitomi, Ryosuke; Koyama, Junji; Tambo, Yuichi; Ogusu, Shinsuke; Saiki, Masafumi; Gyotoku, Hiroshi; Hasegawa, Tsukasa; Miyauchi, Eisaku; Sonoda, Tomoaki; Saito, Ryota; Nakatomi, Katsumi; Sakatani, Toshio; Kudo, Keita; Tsuchiya-Kawano, Yuko; Nishio, Makoto
Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non–small cell lung cancer: exploratory analysis of a prospective observational study

免疫相关基因表达谱分析与阿来替尼对ALK重排非小细胞肺癌患者的疗效：前瞻性观察性研究的探索性分析

Lung Cancer
IF4.4
2026-04-190
PRE
Takashi Kurosaki; Shinichiro Suzuki; Yasutaka Watanabe; Hirotsugu Kenmotsu; Shoichi Itoh; Masafumi Yamaguchi; Ayako Shiono; Takuji Suzuki; Toshihide Yokoyama; Yukihiro Toi; Hisashi Tanaka; Masahide Oki; Takeshi Tsuda; Eiki Ichihara; Koichi Azuma; Hiroshi Tanaka; Ryo Arai; Ken Uchibori; Eisaku Miyauchi; Ryohei Katayama
Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2

J-TAIL-2研究中接受阿替利珠单抗联合疗法治疗的肺癌患者血浆蛋白质组学分析用于生物标志物发现

Cancer Science
IF4.3
2026-04-010
OAAI
Goto, Yasushi; Nishio, Makoto; Ohashi, Kadoaki; Osoegawa, Atsushi; Kikuchi, Eiki; Kimura, Hideharu; Shimizu, Junichi; Miyauchi, Eisaku; Yoshioka, Hiroshige; Yoshino, Ichiro; Misumi, Toshihiro; Watanabe, Yasutaka; Katakami, Nobuyuki; Kisohara, Akira; Yamaguchi, Masafumi; Kuroki, Hirotaka; Sugimoto, Masamichi; Ashimura, Hisao; Tanaka, Misa; Gemma, Akihiko
A Phase 2 study of osimertinib in combination with platinum-pemetrexed in patients with uncommon epidermal growth factor receptor-mutated advanced non-small cell lung cancer (NEJ067/OPAL2)

一项奥希替尼联合铂类-培美曲塞治疗 uncommon epidermal growth factor receptor-mutated advanced non-small cell lung cancer（NEJ067/OPAL2）的II期研究

Clinical Lung Cancer
IF3.3
2025-08-260
PRE
Daisuke Morinaga; Megumi Furuta; Satoshi Morita; Eisaku Miyauchi; Kunihiko Kobayashi; Makoto Maemondo; Hajime Asahina
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B Study

一项关于阿法替尼与培美曲塞和卡铂联合治疗EGFR突变阳性、非鳞状、晚期非小细胞肺癌（NSCLC）患者（对一线奥希替尼治疗耐药）的II期研究：NEJ025B研究

European Journal of Cancer
IF7.1
2025-08-200
PRE
Hiromi Nagashima; Tatsuro Fukuhara; Yu Utsumi; Aya Suzuki; Akihiko Miyanaga; Masahiro Seike; Koichi Azuma; Hajime Asahina; Akira Kisohara; Yosuke Kawashima; Hisashi Tanaka; Ryota Kanemaru; Eisaku Miyauchi; Naoki Furuya; Haruna Sato; Kazuhisa Nakashima; Satoshi Watanabe; Kazuko Sakai; Kazuto Nishio; Fumiaki Takahashi; Kunihiko Kobayashi; Makoto Maemondo
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors

LP-300联合卡铂和培美曲塞治疗既往接受过酪氨酸激酶抑制剂治疗的从不吸烟的复发进展期原发性肺腺癌患者的II期临床试验

Clinical Lung Cancer
IF3.3
2025-05-280
PRE
J. Nicholas Bodor; Jonathan Dowell; Joseph Treat; Janakiraman Subramanian; Nihal Abdulla; Eric Lee; Kamlesh Sankhala; Chun-Hui Lee; Go Makimoto; Eisaku Miyauchi; Kartik Konduri; Hajime Asahina; Shuji Murakami; Yueh-Feng Wen; Yung-Hung Luo; Shan Yueh Chang; Reginald Ewesuedo; Jianli Zhou; Yasushi Goto
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

Durvalumab在表皮生长因子受体突变型III期非小细胞肺癌患者接受同步化放疗后的应用：一项日本真实世界数据分析

Lung Cancer
IF4.4
2025-05-270
OA
Toshiya Fujisaki; Eisaku Miyauchi; Gen Kida; Yu Miura; Kana Watanabe; Hironori Ashinuma; Motohiro Tamiya; Hajime Kikuchi; Daisuke Arai; Satoshi Takahashi; Ken Masuda; Ayako Takigami; Yoshiaki Nagai; Taichi Miyawaki; Yukari Tsubata; Akira Nakao; Ken Masubuchi; Kazuhiro Nishiyama; Satoshi Watanabe; Satoshi Morita; Makoto Maemondo
Regional Differences in the Frequency of BRCA1 and BRCA2 Variants in Northeastern Japan: A Cohort Study

东北地区BRCA1和BRCA2变异频率的区域差异：一项队列研究

CANCER MEDICINE
IF3.1
2025-04-180
OA
Shirota, Hidekazu; Miyake, Akimitsu; Kawamura, Maako; Suzuki, Shuhei; Saito, Kensuke; Yasuda, Jun; Shibata, Hiroyuki; Saito, Motonobu; Iwaya, Takeshi; Tada, Hiroshi; Shimada, Muneaki; Kawamorita, Naoki; Kanamori, Masayuki; Miyauchi, Eisaku; Niizuma, Hidetaka; Iwasaki, Tomoyuki; Kasahara, Yuki; Imai, Hiroo; Saijo, Ken; Komine, Keigo; Takahashi, Masanobu; Niihori, Tetsuya; Aoki, Yoko; Furukawa, Toru; Tamiya, Gen; Ishioka, Chikashi
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study

30天内出现皮肤疾病是接受尼妥珠单抗联合吉西他滨和顺铂治疗的肺鳞状细胞癌患者的有利预后因素：NINJA研究的亚组分析

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2025-03-150
OA
Fumihiko Kinoshita; Shigeru Tanzawa; Toshihiro Misumi; Hiroshige Yoshioka; Eisaku Miyauchi; Kiichiro Ninomiya; Yasunori Murata; Masafumi Takeshita; Masafumi Yamaguchi; Shunichi Sugawara; Yosuke Kawashima; Kazuki Hashimoto; Masahide Mori; Akihiko Miyanaga; Anna Hayashi; Hisashi Tanaka; Ryoichi Honda; Masafumi Nojiri; Yuki Sato; Ken Yamamoto; Ken Masuda; Toshiyuki Kozuki; Takahisa Kawamura; Takuji Suzuki; Teppei Yamaguchi; Kazuhiro Asada; Satoshi Tetsumoto; Hiroshi Tanaka; Satoshi Watanabe; Yukihiro Umeda; Kakuhiro Yamaguchi; Shoichi Kuyama; Kosuke Tsuruno; Yuki Misumi; Hiroshi Kuraishi; Ken Yoshihara; Akira Nakao; Akihito Kubo; Toshihiko Yokoyama; Kana Watanabe; Nobuhiko Seki
J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2025-03-010
OA
Miyauchi, Eisaku; Nishio, Makoto; Ohashi, Kadoaki; Osoegawa, Atsushi; Kikuchi, Eiki; Kimura, Hideharu; Goto, Yasushi; Shimizu, Junichi; Yoshioka, Hiroshige; Yoshino, Ichiro; Misumi, Toshihiro; Katakami, Nobuyuki; Oki, Masahide; Kijima, Takashi; Chikamori, Kenichi; Nishino, Kazumi; Kobayashi, Yuki; Miwa, Asako; Tanaka, Misa; Gemma, Akihiko
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study

尼妥珠单抗联合顺铂和吉西他滨治疗在晚期肺鳞状细胞癌患者中诱导低镁血症的临床影响：NINJA研究的亚组分析

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2025-02-140
OA
Shigeru Tanzawa; Hiroshige Yoshioka; Toshihiro Misumi; Eisaku Miyauchi; Kiichiro Ninomiya; Yasunori Murata; Masafumi Takeshita; Fumihiko Kinoshita; Takatoshi Fujishita; Shunichi Sugawara; Yosuke Kawashima; Kazuki Hashimoto; Masahide Mori; Akihiko Miyanaga; Anna Hayashi; Hisashi Tanaka; Ryoichi Honda; Masafumi Nojiri; Yuki Sato; Akito Hata; Nobuhisa Ishikawa; Toshiyuki Kozuki; Takahisa Kawamura; Go Saito; Teppei Yamaguchi; Kazuhiro Asada; Satoshi Tetsumoto; Hiroshi Tanaka; Satoshi Watanabe; Yukihiro Umeda; Kakuhiro Yamaguchi; Kazuya Nishii; Kosuke Tsuruno; Yuki Misumi; Hiroshi Kuraishi; Ken Yoshihara; Akira Nakao; Akihito Kubo; Toshihiko Yokoyama; Kana Watanabe; Nobuhiko Seki
Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902

先前未经治疗的转移性NSCLC患者联合放疗和Pembrolizumab加化疗的2期试验: NJLCG 1902

JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2025-02-010
OA
Tsukita, Yoko; Umezawa, Rei; Nakagawa, Taku; Anbai, Akira; Makiguchi, Tomonori; Tanaka, Hisashi; Horii, Yosuke; Suzuki, Aya; Morita, Ryo; Nogawa, Hitomi; Yokouchi, Hiroshi; Kimura, Nozomu; Jingu, Keiichi; Inoue, Akira; Sugiura, Hisatoshi; Miyauchi, Eisaku
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

广泛期小细胞肺癌根据关键临床试验入组标准进行的化疗免疫疗法长期预后：一项前瞻性队列研究的3年结果

LUNG CANCER
IF4.4
2025-01-010
PRE
Sugisaka, Jun; Fujimoto, Daichi; Tamiya, Motohiro; Hata, Akito; Matsumoto, Hirotaka; Yokoyama, Toshihide; Taniguchi, Yoshihiko; Uchida, Junji; Sato, Yuki; Kijima, Takashi; Tanaka, Hisashi; Furuya, Naoki; Masuda, Takeshi; Sakata, Yoshihiko; Miyauchi, Eisaku; Saito, Go; Miura, Satoru; Yamaguchi, Teppei; Daga, Haruko; Sakata, Shinya; Yamamoto, Nobuyuki; Akamatsu, Hiroaki
Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK plus NSCLC): Second interim analysis of ALCURE

ALK易位非小细胞肺癌（ALK plus NSCLC）患者中，一线（1L）阿来替尼的耐药机制与疗效：ALCURE研究的第二次中期分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Mouri, A.; Tsuda, T.; Oki, M.; Ichihara, E.; Tanaka, H.; Azuma, K.; Arai, R.; Kuyama, S.; Akamatsu, H.; Otsubo, K.; Ajimizu, H.; Matsumoto, M.; Seto, Y.; Uchibori, K.; Hayashi, H.; Miyauchi, E.; Ishizuka, N.; Kajihara, Y.; Nakagawa, Y.; Katayama, R.
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49%): TOPGAN2023-01
EUROPEAN JOURNAL OF CANCER
IF7.1
2024-12-010
PRE
Tanaka, Hisashi; Makiguchi, Tomonori; Tozuka, Takehiro; Kawashima, Yosuke; Oba, Tomohiro; Tsugitomi, Ryosuke; Koyama, Junji; Tambo, Yuichi; Ogusu, Shinsuke; Saiki, Masafumi; Gyotoku, Hiroshi; Hasegawa, Tsukasa; Miyauchi, Eisaku; Sonoda, Tomoaki; Saito, Ryota; Nakatomi, Katsumi; Sakatani, Toshio; Kudo, Keita; Tsuchiya-Kawano, Yuko; Nishio, Makoto

研究方向

暂未获取到该数据
H
Hisatoshi Sugiura
H 指数:44论文数:326被引数:7,133
H
Hiroshige Yoshioka
H 指数:49论文数:356被引数:1.6万
Y
Yoko Tsukita
H 指数:13论文数:73被引数:725
H
Hisashi Tanaka
H 指数:19论文数:167被引数:1,133
T
Toshihiro Misumi
H 指数:20论文数:323被引数:2,505
M
Makoto Nishio
H 指数:69论文数:864被引数:3.0万
S
Satoshi Morita
H 指数:85论文数:1,269被引数:4.0万
M
Motohiro Tamiya
H 指数:32论文数:372被引数:3,542
A
Akito Hata
H 指数:30论文数:240被引数:2,577
S
Satoshi Watanabe
H 指数:40论文数:453被引数:9,078